MAMaryam Althobiti

Maryam Althobiti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryam Althobiti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Emad A. Rakha

    Academic Unit for Translational Medical Sciences, School of Medicine University of Nottingham Nottingham UK

    4 shared publications
  • Mohammed A. Aleskandarany

    Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, UK

    4 shared publications
  • Andrew R. Green

    Nottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK

    2 shared publications
  • Chitra Joseph

    Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham, University Park, Nottingham, England

    2 shared publications
  • Chitra Joseph

    Respiratory Medicine NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK

    2 shared publications
  • Michael S. Toss

    Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham, University Park, Nottingham, England

    2 shared publications

Latest Publications

  • Open Access

    Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer

    by Maryam Althobiti, Khloud A. El-Sharawy, Chitra Joseph, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Emad A. Rakha

    Purpose: The outcome of the luminal oestrogen receptor-positive (ER +) subtype of breast cancer (BC) is highly variable and patient stratification needs to be refined. We assessed the prognostic significance of oestrogen-regulated solute carrier family 39 member 6 (SLC39A6) in BC, with emphasis on ER + tumours. Materials and methods: SLC39A6 mRNA expression and copy number alterations were assessed using the METABRIC cohort (n = 1980). SLC39A6 protein expression was evaluated in a large (n = 670) and annotated series of early-stage (I–III) operable BC using tissue microarrays and immunohistochemistry. The associations between SLC39A6 expression and clinicopathological parameters, patient outcomes and other ER-related markers were evaluated using Chi-square tests and Kaplan–Meier curves. Results: High SLC39A6 mRNA and protein expression was associated with features characteristic of less aggressive tumours in the entire BC cohort and ER + subgroup. SLC39A6 protein expression was detected in the cytoplasm and nuclei of the tumour cells. High SLC39A6 nuclear expression and mRNA levels were positively associated with ER + tumours and expression of ER-related markers, including the progesterone receptor, forkhead box protein A1 and GATA binding protein 3. In the ER + luminal BC, high SLC39A6 expression was independently associated with longer BC-specific survival (BCSS) (P = 0.015, HR 0.678, 95% CI 0.472‒0.972) even in those who did not receive endocrine therapy (P = 0.001, HR 0.701, 95% CI 0.463‒1.062). Conclusion: SLC39A6 may be prognostic for a better outcome in ER + luminal BC. Further functional studies to investigate the role of SLC39A6 in ER + luminal BC are warranted.


  • Open Access

    The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes

    by Maryam Althobiti, Abir A. Muftah, Mohammed A. Aleskandarany, Chitra Joseph, Michael S. Toss, Andrew Green, Emad Rakha

    Purpose: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we have evaluated the prognostic significance of BMI1 among the different molecular subtypes and assessed its association with other breast CSC markers (BCSC). Material and method: BMI1 copy number and mRNA was assessed in large and well-characterised cohorts of early-stage BC patients [METABRIC (n = 1980) and the Bc-GenExMiner (n = 9616) databases]. BMI1 protein expression was assessed using tissue microarray and immunohistochemistry in a cohort of 870 invasive BC patients with long-term outcome data and the expression of a panel of BCSC markers was monitored. Result: BMI1 expression, prognostic significance and its association with BCSC markers were differed between molecular classes. In the luminal oestrogen receptor-positive (ER+) BC, BMI1 showed significantly higher expression compared to ER− tumours. BMI1 showed positive correlation with favourable prognostic features and it was negatively associated with the expression of key BCSC markers (ALDH1A1, CD24, CD44, CD133, SOX10 and SOX9). High expression of BMI1 was associated with longer breast cancer-specific survival (BCSS) independent of other prognostic variables. In the basal triple negative BC subtype, BMI1 expression showed positive association with CD133 and SOX10 and it was significantly associated with shorter BCSS. Conclusion: High BMI1 expression is associated with clinicopathological variables and outcome in BC. However, this association is dependent on the molecular subtypes. Further functional assessment to detect its underlying mechanistic roles in BC subtypes is warranted.


  • Open Access

    The prognostic significance of ALDH1A1 expression in early invasive breast cancer

    by Maryam Althobiti, Rokaya El Ansari, Mohammed Aleskandarany, Chitra Joseph, Michael S Toss, Andrew R Green, Emad A Rakha

    Aims: Aldehyde dehydrogenase family 1 member A1 (ALDH1A1) is reportedly a key ALDH isozyme linked to the cancer stem cells (CSC) of many solid tumours, where it is involved in self‐renewal, differentiation and self‐protection. In this study, the prognostic significance of ALDH1A1 expression in early invasive breast cancer (BC) and its role as a BC stem cell (BCSC) were evaluated.Methods and results: ALDH1A1 expression was assessed, using immunohistochemistry and tissue microarrays, in a large well‐characterised BC cohort. ALDH1A1 mRNA expression was also assessed at transcriptomic levels, utilising data from the Molecular Taxonomy of Breast Cancer International Consortium. The associations of ALDH1A1 with clinicopathological parameters, other stem cell markers and patient outcomes were determined. ALDH1A1 was expressed in 71% of BC cases at both the protein and mRNA levels. High ALDH1A1 expression was associated with poor prognostic features, including high grade, poor Nottingham Prognostic Index (NPI), lymph node metastasis and highly proliferative ER+ (luminal B) and triple‐negative (TNBC) subtypes. ALDH1A1 expression was positively correlated with the expression of CD44, CD24, TWIST, SOX9, EPCAM and CD133. The high immunoexpression of ALDH1A1 was significantly associated with poor BC‐specific survival (P < 0.001), and specifically in the luminal B and TNBC subtypes (P = 0.042 and P = 0.003, respectively). The immunoexpression of ALDH1A1 was an independent predictor of poor prognosis (P = 0.015).Conclusions: ALDH1A1, as assessed using immunohistochemistry, seems to act as a BCSC marker associated not only with other BCSC markers but also with poor prognostic characteristics and poor outcomes, particularly in the luminal B and TNBC subtypes.


  • Heterogeneity of tumour‐infiltrating lymphocytes in breast cancer and its prognostic significance

    by Maryam Althobiti, Mohammed A Aleskandarany, Chitra Joseph, Michael Toss, Nigel Mongan, Maria Diez‐Rodriguez, Christopher C Nolan, Ibraheem Ashankyty, Ian O Ellis, Andrew R Green, et al.

    Background and aims: Tumour‐infiltrating lymphocytes (TILs) in breast cancer (BC) provide prognostic and predictive information. The aim of this study was to assess the spatial and temporal heterogeneity of TILs in BC and its relationship with immune cell subtypes.Methods and results: Immunohistochemically defined immune cell subtypes, i.e. those expressing T‐cell markers (CD3, CD8, and FOXP3), a B‐cell marker (CD20) and a histiocytic marker (CD68), were evaluated in a large series (n = 1165) of invasive BCs. A subset of full‐face haematoxylin and eosin (H&E)‐stained slides were examined for TILs heterogeneity within primary tumours and the corresponding local recurrent carcinomas to investigate spatial and temporal TILs heterogeneity. H&E‐stained sections from multiple tumour blocks (three or four blocks per case) representing different tumour areas were evaluated to assess TILs interslide heterogeneity and intraslide heterogeneity. Both average stromal TILs (AV‐TILs) and hotspot stromal TILs (HS‐TILs) were assessed. AV‐TILs showed associations with all immune cell subtypes; however, CD3+ cells constituted the main component (mean number of CD3+ was 55), whereas CD20+ cells constituted the smallest component (mean number of CD20 was 13). There was no significant statistical difference between TILs across tumour blocks of the same case (P = 0.251 for AV‐TILs and P = 0.162 for HS‐TILs). Triple‐negative breast cancer (TNBC) showed higher TILs percentage than other BC subtypes (P < 0.001). High AV‐TILs, CD3+ cells, CD8+ cells and CD20+ cells were associated with longer survival in TNBC patients (P < 0.05). High AV‐TILs in recurrent tumours showed a significant association with shorter post‐recurrence survival (P = 0.004).Conclusions: Despite the heterogeneity of immune cell type components, average TILs in one full‐face H&E‐stained section reliably represent TILs in the whole tumour. TILs were associated with outcome in TNBC patients, as well as having prognostic significance for recurrent tumours.